当前位置： SCI文献检索 > MOLECULAR CANCER THERAPEUTICS期刊下所有文献 > G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium.

G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium.

Abstract：

:Because proliferation of eukaryotic cells requires cell cycle-regulated chromatid separation by the mitotic spindle, it is subject to regulation by mitotic checkpoints. To determine the mechanism of the antiproliferative activity of the flavoprotein-specific inhibitor diphenyleneiodonium (DPI), I have examined its effect on the cell cycle and mitosis. Similar to paclitaxel, exposure to DPI causes an accumulation of cells with a 4N DNA content. However, unlike the paclitaxel-mediated mitotic block, DPI-treated cells are arrested in the cell cycle prior to mitosis. Although DPI-treated cells can arrest with fully separated centrosomes at opposite sides of the nucleus, these centrosomes fail to assemble mitotic spindle microtubules and they do not accumulate the Thr(288) phosphorylated Aurora-A kinase marker of centrosome maturation. In contrast with paclitaxel-arrested cells, DPI impairs cyclin B1 accumulation. Release from DPI permits an accumulation of cyclin B1 and progression of the cells into mitosis. Conversely, exposure of paclitaxel-arrested mitotic cells to DPI causes a precipitous drop in cyclin B and Thr(288) phosphorylated Aurora-A levels and leads to mitotic catastrophe in a range of cancerous and noncancerous cells. Hence, the antiproliferative activity of DPI reflects a novel inhibitory mechanism of cell cycle progression that can reverse spindle checkpoint-mediated cell cycle arrest.

journal_name

Mol Cancer Ther

journal_title

Molecular cancer therapeutics

authors

Scaife RM

keywords:

subject

Has Abstract

pub_date

2004-10-01 00:00:00

pages

1229-37

issue

10

eissn

1535-7163

issn

1538-8514

pii

3/10/1229

journal_volume

3

pub_type

杂志文章

相关文献

MOLECULAR CANCER THERAPEUTICS文献大全
  • Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

    abstract：:Vascular endothelial growth factor (VEGF) is a primary stimulant of angiogenesis and is a macrophage chemotactic protein. Inhibition of VEGF is beneficial in combination with chemotherapy for some breast cancer patients. However, the mechanism by which inhibition of VEGF affects tumor growth seems to involve more than...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0280

    authors： Roland CL,Dineen SP,Lynn KD,Sullivan LA,Dellinger MT,Sadegh L,Sullivan JP,Shames DS,Brekken RA

    更新日期：2009-07-01 00:00:00

  • Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2.

    abstract：:Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase-2 (COX2) activity by nonsteroidal anti-inflammatory drugs (NSAID) can both attenuate skin tumorigenesis. The present study examined the hypothesis that combining ligand activation of PPARβ/δ with inhibition o...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-10-0820

    authors： Zhu B,Bai R,Kennett MJ,Kang BH,Gonzalez FJ,Peters JM

    更新日期：2010-12-01 00:00:00

  • Evading Pgp activity in drug-resistant cancer cells: a structural and functional study of antitubulin furan metotica compounds.

    abstract：:Tumor resistance to antitubulin drugs resulting from P-glycoprotein (Pgp) drug-efflux activity, increased expression of the βIII tubulin isotype, and alterations in the drug-binding sites are major obstacles in cancer therapy. Consequently, novel antitubulin drugs that overcome these challenges are of substantial inte...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-11-1018

    authors： Nguyen TL,Cera MR,Pinto A,Lo Presti L,Hamel E,Conti P,Gussio R,De Wulf P

    更新日期：2012-05-01 00:00:00

  • 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.

    abstract：:Tumor cells are efficiently killed after incubation with alpha-emitter immunoconjugates targeting tumor-specific antigens. Therefore, application of alpha-emitter immunoconjugates is a promising therapeutic option for treatment of carcinomas that are characterized by dissemination of single tumor cells in the peritone...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0132

    authors： Seidl C,Port M,Gilbertz KP,Morgenstern A,Bruchertseifer F,Schwaiger M,Röper B,Senekowitsch-Schmidtke R,Abend M

    更新日期：2007-08-01 00:00:00

  • Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.

    abstract：:The tyrosine kinase receptor c-Met and its ligand hepatocyte growth factor (HGF) are frequently overexpressed and the tumor suppressor PTEN is often mutated in glioblastoma. Because PTEN can interact with c-Met-dependent signaling, we studied the effects of PTEN on c-Met-induced malignancy and associated molecular eve...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-08-0627

    authors： Li Y,Guessous F,DiPierro C,Zhang Y,Mudrick T,Fuller L,Johnson E,Marcinkiewicz L,Engelhardt M,Kefas B,Schiff D,Kim J,Abounader R

    更新日期：2009-02-01 00:00:00

  • p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc.

    abstract：:Ascofuranone has been shown to have antitumor activity, but the precise molecular mechanism by which it inhibits the proliferation of cancer cells remains unclear. Here, we study the effects of ascofuranone on cell cycle progression in human cancer cells and find that ascofuranone induces G(1) arrest without cytoxicit...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-1159

    authors： Jeong JH,Kang SS,Park KK,Chang HW,Magae J,Chang YC

    更新日期：2010-07-01 00:00:00

  • Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.

    abstract：:The epidermal growth factor receptor (EGFR) and hedgehog cascades provide a critical role in prostate cancer progression and contribute to the resistance to clinical therapies and disease relapse. Therefore, we evaluated, for the first time, the antiproliferative and cytotoxic effects induced by a combination of selec...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0648

    authors： Mimeault M,Johansson SL,Vankatraman G,Moore E,Henichart JP,Depreux P,Lin MF,Batra SK

    更新日期：2007-03-01 00:00:00

  • The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors.

    abstract：:Acquired resistance severely hinders the application of small-molecule inhibitors. Our understanding of acquired resistance related to FGFRs is limited. Here, to explore the underlying mechanism of acquired resistance in FGFR-aberrant cancer cells, we generated cells resistant to multiple FGFR inhibitors (FGFRi) and i...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-0179

    authors： Wang X,Ai J,Liu H,Peng X,Chen H,Chen Y,Su Y,Shen A,Huang X,Ding J,Geng M

    更新日期：2019-03-01 00:00:00

  • Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor.

    abstract：:Tumors can exploit the indoleamine 2,3-dioxygenase 1 (IDO1) pathway to create an immunosuppressive microenvironment. Activated IDO1 metabolizes tryptophan into immunosuppressive kynurenine, leading to suppressed effector T-cell (Teff) proliferation, allowing for tumor escape from host immune surveillance. IDO1 inhibit...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-20-0251

    authors： Balog A,Lin TA,Maley D,Gullo-Brown J,Kandoussi EH,Zeng J,Hunt JT

    更新日期：2020-12-09 00:00:00

  • Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.

    abstract：:Insulin-like growth factor-I receptor (IGF-IR) is an important mediator of tumor cell survival and shows prognostic significance in sarcoma. To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of cyclolignan picropodophyllin (PPP), a member of the cyclol...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0115

    authors： Duan Z,Choy E,Harmon D,Yang C,Ryu K,Schwab J,Mankin H,Hornicek FJ

    更新日期：2009-08-01 00:00:00

  • Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.

    abstract：:NB1011, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. NB1011 is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis. NB1011 is different from the current TS-targeted drugs, ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Neuteboom ST,Karjian PL,Boyer CR,Beryt M,Pegram M,Wahl GM,Shepard HM

    更新日期：2002-04-01 00:00:00

  • Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.

    abstract：:The type I EGF receptor (EGFR or ErbB1) and insulin-like growth factor-binding protein-3 (IGFBP-3) are highly expressed in triple-negative breast cancer (TNBC), a particularly aggressive disease that cannot be treated with conventional therapies targeting the estrogen or progesterone receptors (ER and PR), or HER2. We...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0367

    authors： Martin JL,de Silva HC,Lin MZ,Scott CD,Baxter RC

    更新日期：2014-02-01 00:00:00

  • Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly.

    abstract：:The CDC25 cell cycle regulators are promising targets for new pharmacologic approaches in cancer therapy. Inhibitory compounds such as BN82685 have proven to be effective in specifically targeting CDC25 in cultured cells and in inhibiting tumor cell growth. Here, we report that BN82685 impairs microtubule dynamic inst...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-06-0299

    authors： Cazales M,Boutros R,Brezak MC,Chaumeron S,Prevost G,Ducommun B

    更新日期：2007-01-01 00:00:00

  • p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR.

    abstract：:High Mycoplasma infection in gastric cancer tissues suggests a possible association between Mycoplasma infection and tumorigenesis. By using human gastric cancer cells AGS and mouse melanoma cells B16F10 stably expressing p37, the major immunogen of Mycoplasma hyorhinis, we found that p37 enhanced cell motility, migra...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-2191

    authors： Gong M,Meng L,Jiang B,Zhang J,Yang H,Wu J,Shou C

    更新日期：2008-03-01 00:00:00

  • Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.

    abstract：:The advent of multikinase inhibitors targeting the vascular endothelial growth factor (VEGF) receptor has revolutionized the treatment of highly angiogenic malignancies such as renal cell carcinoma. Interestingly, several such inhibitors are commercially available, and they each possess diverse specific beneficial and...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0119

    authors： Liu JY,Park SH,Morisseau C,Hwang SH,Hammock BD,Weiss RH

    更新日期：2009-08-01 00:00:00

  • Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells.

    abstract：:Streptozotocin-based chemotherapy is the first-line chemotherapy recommended for advanced pancreatic neuroendocrine tumors (pNETs), whereas targeted therapies, including mTOR inhibitors, are available in second-line treatment. Unfortunately, objective response rates to both treatments are limited. Because mTOR pathway...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-0325

    authors： Bollard J,Patte C,Massoma P,Goddard I,Gadot N,Benslama N,Hervieu V,Ferraro-Peyret C,Cordier-Bussat M,Scoazec JY,Roche C,Walter T,Vercherat C

    更新日期：2018-01-01 00:00:00

  • Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

    abstract：:Inactivation of NF2/Merlin causes the autosomal-dominant cancer predisposition syndrome familial neurofibromatosis type 2 (NF2) and contributes to the development of malignant pleural mesothelioma (MPM). To develop a targeted therapy for NF2-mutant tumors, we have exploited the recent realization that Merlin loss driv...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-16-0821

    authors： Cooper J,Xu Q,Zhou L,Pavlovic M,Ojeda V,Moulick K,de Stanchina E,Poirier JT,Zauderer M,Rudin CM,Karajannis MA,Hanemann CO,Giancotti FG

    更新日期：2017-08-01 00:00:00

  • Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.

    abstract：:Anti-HER2/CD3, a T-cell-dependent bispecific antibody (TDB) construct, induces T-cell-mediated cell death in cancer cells expressing HER2 by cross-linking tumor HER2 with CD3 on cytotoxic T cells, thereby creating a functional cytolytic synapse. TDB design is a very challenging process that requires consideration of m...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-0657

    authors： Mandikian D,Takahashi N,Lo AA,Li J,Eastham-Anderson J,Slaga D,Ho J,Hristopoulos M,Clark R,Totpal K,Lin K,Joseph SB,Dennis MS,Prabhu S,Junttila TT,Boswell CA

    更新日期：2018-04-01 00:00:00

  • Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer.

    abstract：:Our previous studies and those of others have indicated that X-linked inhibitor of apoptosis protein (XIAP) holds promise as a target gene in colon cancer gene therapy. In this study, we constructed an adenoviral vector to deliver small hairpin RNA (shRNA) against XIAP (XIAP-shRNA) into colon cancer cells and tested i...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0509

    authors： Dai Y,Qiao L,Chan KW,Yang M,Ye J,Zhang R,Ma J,Zou B,Lam CS,Wang J,Pang R,Tan VP,Lan HY,Wong BC

    更新日期：2009-09-01 00:00:00

  • A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.

    abstract：:DNA damaging agents such as cisplatin arrest cell cycle progression at either G1, S, or G2 phase, although the G1 arrest is only seen in cells expressing the wild-type p53 tumor suppressor protein. We have reported that 7-hydroxystaurosporine (UCN-01) overcomes S and G2 phase arrest and enhances the cytotoxicity of ci...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Eastman A,Kohn EA,Brown MK,Rathman J,Livingstone M,Blank DH,Gribble GW

    更新日期：2002-10-01 00:00:00

  • Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

    abstract：:Clear cell renal cell carcinoma (CC-RCC) is a devastating disease with limited therapeutic options available for advanced stages. The objective of this study was to investigate HMG-CoA reductase inhibitors, also known as statins, as potential therapeutics for CC-RCC. Importantly, treatment with statins was found to be...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-1076

    authors： Thompson JM,Alvarez A,Singha MK,Pavesic MW,Nguyen QH,Nelson LJ,Fruman DA,Razorenova OV

    更新日期：2018-08-01 00:00:00

  • The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.

    abstract：:G-protein mutations are one of the most common mutations occurring in uveal melanoma activating the protein kinase C (PKC)/mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K)/AKT pathways. In this study, we described the effect of dual pathway inhibition in uveal melanoma harboring GNAQ and GNA11 mut...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0550

    authors： Musi E,Ambrosini G,de Stanchina E,Schwartz GK

    更新日期：2014-05-01 00:00:00

  • Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis.

    abstract：:Emerging evidence suggests that autophagic modulators have therapeutic potential. This study aims to identify novel autophagic inducers from traditional Chinese medicinal herbs as potential antitumor agents. Using an image-based screen and bioactivity-guided purification, we identified alisol B 23-acetate, alisol A 24...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-09-0700

    authors： Law BY,Wang M,Ma DL,Al-Mousa F,Michelangeli F,Cheng SH,Ng MH,To KF,Mok AY,Ko RY,Lam SK,Chen F,Che CM,Chiu P,Ko BC

    更新日期：2010-03-01 00:00:00

  • Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway.

    abstract：:Oncostatin M (OSM), an interleukin 6-type cytokine, induces sustained up-regulation of CCAAT/enhancer-binding protein (C/EBP) delta mRNA and protein in nonneoplastic HC11 mouse mammary epithelial cells. This up-regulation is dependent on signaling by phospho-Stat3 (signal transducers and activators of transcription). ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：

    authors： Hutt JA,DeWille JW

    更新日期：2002-06-01 00:00:00

  • A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κB.

    abstract：:Fas-associated protein with death domain (FADD) is a cytosolic adapter protein essential for mediating death receptor-induced apoptosis. It has also been implicated in a number of nonapoptotic activities including embryogenesis, cell-cycle progression, cell proliferation, and tumorigenesis. Our recent studies have sho...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-11-0362

    authors： Schinske KA,Nyati S,Khan AP,Williams TM,Johnson TD,Ross BD,Tomás RP,Rehemtulla A

    更新日期：2011-10-01 00:00:00

  • Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

    abstract：:Notch signaling is aberrantly activated in approximately one third of non-small cell lung cancers (NSCLC). We characterized the interaction between BMS-906024, a clinically relevant Notch gamma secretase inhibitor, and front-line chemotherapy in preclinical models of NSCLC. Chemosensitivity assays were performed on 14...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-17-0439

    authors： Morgan KM,Fischer BS,Lee FY,Shah JJ,Bertino JR,Rosenfeld J,Singh A,Khiabanian H,Pine SR

    更新日期：2017-12-01 00:00:00

  • LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.

    abstract：:Targeting inhibitor of apoptosis proteins (IAP) with second mitochondria-derived activator of caspase (SMAC) mimetics may promote cancer cell death. We tested whether cIAP1 predicts poor prognosis in head and neck squamous cell carcinoma (HNSCC) and whether a novel Smac-mimetic, LCL161, could radiosensitize human papi...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-18-1157

    authors： Yang L,Kumar B,Shen C,Zhao S,Blakaj D,Li T,Romito M,Teknos TN,Williams TM

    更新日期：2019-06-01 00:00:00

  • z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo.

    abstract：:Our previous studies have shown that z-guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. We now report a novel response to z-guggulsterone involving the inhibition of angiogenesis in vitro and in vivo. The z-guggu...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-07-0491

    authors： Xiao D,Singh SV

    更新日期：2008-01-01 00:00:00

  • Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

    abstract：:DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1158/1535-7163.MCT-15-0693

    authors： Weekes CD,Lamberts LE,Borad MJ,Voortman J,McWilliams RR,Diamond JR,de Vries EG,Verheul HM,Lieu CH,Kim GP,Wang Y,Scales SJ,Samineni D,Brunstein F,Choi Y,Maslyar DJ,Colon-Otero G

    更新日期：2016-03-01 00:00:00

  • Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.

    abstract：:Many malignant human tumors, including melanomas, are auxotrophic for arginine due to reduced expression of argininosuccinate synthetase-1 (ASS1), the rate-limiting enzyme for arginine biosynthesis. Pegylated arginine deiminase (ADI-PEG20), which degrades extracellular arginine, resulting in arginine deprivation, has ...

    journal_title：Molecular cancer therapeutics

    pub_type： 杂志文章

    doi：10.1158/1535-7163.MCT-13-0302

    authors： Long Y,Tsai WB,Wangpaichitr M,Tsukamoto T,Savaraj N,Feun LG,Kuo MT

    更新日期：2013-11-01 00:00:00